Drug Information

Drug General Information
Drug ID
D0V4RZ
Former ID
DNC008995
Drug Name
WAY-214950
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529781]
Structure
Download
2D MOL

3D MOL
Formula
C21H13F5N2
Canonical SMILES
C1=CC=C(C(=C1)CN2C(=C3C=CC=C(C3=N2)C(F)(F)F)C4=CC=C(C=C<br />4)F)F
InChI
1S/C21H13F5N2/c22-15-10-8-13(9-11-15)20-16-5-3-6-17(21(24,25)26)19(16)27-28(20)12-14-4-1-2-7-18(14)23/h1-11H,12H2
InChIKey
NHSFDMDEDPAKNH-UHFFFAOYSA-N
PubChem Compound ID
25113722
Target and Pathway
Target(s) Oxysterols receptor LXR-beta Target Info Inhibitor [529781]
Pregnane X receptor Target Info Inhibitor [529781]
Oxysterols receptor LXR-alpha Target Info Inhibitor [529781]
mRNA of glucocorticoid receptor Target Info Inhibitor [529781]
KEGG Pathway PPAR signaling pathway
Non-alcoholic fatty liver disease (NAFLD)
Hepatitis Chsa04080:Neuroactive ligand-receptor interaction
NetPath Pathway IL2 Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptorsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
Signaling events mediated by HDAC Class II
FOXA2 and FOXA3 transcription factor networks
Glucocorticoid receptor regulatory network
Regulation of Androgen receptor activity
AP-1 transcription factor network
Reactome Nuclear Receptor transcription pathwayR-HSA-1368108:BMAL1:CLOCK,NPAS2 activates circadian gene expression
WikiPathways SREBP signalling
Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity
Nuclear Receptors Meta-Pathway
Pregnane X Receptor pathway
Drug Induction of Bile Acid Pathway
PPAR Alpha Pathway
Liver X Receptor Pathway
Adipogenesis
SREBF and miR33 in cholesterol and lipid homeostasis
Nuclear ReceptorsWP734:Serotonin Receptor 4/6/7 and NR3C Signaling
SIDS Susceptibility Pathways
Endoderm Differentiation
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Circadian Clock
Nuclear Receptors
References
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.